Immuron Limited

IMRN | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.25

+$0.03 (+2.46%)

At close: Sep 21, 2026, 3:59 PM ET

$1.23

-$0.02 (-1.60%)

After-hours: Sep 21, 2026, 7:42 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+2.46%

(1D)

Rating

Updated: Sep 8, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $8.09M

1D Range

1.19 1.30

52W Range

0.68 2.39

Valuation (TTM)

PE -3.61

PB 1.06

EV/EBITDA -0.56

Valuation (NTM)

Forward PE N/A

Forward PEG -0.13

Price Target N/A

Cash Flow

FCF Yield -28.2%

SBC Adj. FCF Yield -28.2%

SBC Impact N/A

Margins

Gross Margin 64.5%

Operating Margin -61.5%

FCF Margin -41.7%

Growth (CAGR)

Revenue 3Y | 5Y 178.3% | 36.7%

Dil EPS 3Y | 5Y 0.5% | 1.2%

FCF 3Y | 5Y -6.3% | -17.8%

Returns

ROA -29.5%

ROE -31.9%

ROIC -36.4%

Financial Health

Net Cash

A$9.02M ($6.24M)

Current Ratio 7.17

Interest Coverage -321.88

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and ...

Sector Healthcare

Industry Biotechnology

Employees 7

IPO Date Jun 8, 2017

Website www.immuron.com.au

Fiscal Year July - June

Full Company Profile

Latest News

No news articles available yet.

Earnings

Latest Earnings

Aug 28, 2026

EPS

-$0.17

Miss -4657.53%

YoY: -2499.54%

REV

$2.48M

Miss -9.72%

YoY: +15.83%

Next Earnings

Feb 19, 2027

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞